SELB - Selecta Biosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6700
-0.0100 (-0.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.6800
Open3.7000
Bid3.6800 x 1000
Ask3.9600 x 800
Day's Range3.6700 - 3.8400
52 Week Range1.2800 - 4.8300
Volume638,294
Avg. Volume795,873
Market Cap321.087M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-1.0550
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Selecta (SELB) Stock a Solid Choice Right Now?
    Zacks

    Is Selecta (SELB) Stock a Solid Choice Right Now?

    Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • GlobeNewswire

    Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 8:30 a.m. Eastern Time. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform (ImmTOR).

  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Selecta Biosciences, Inc. - SELB
    Newsfile

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Selecta Biosciences, Inc. - SELB

    New York, New York--(Newsfile Corp. - May 20, 2020) -  Levi & Korsinsky announces it has commenced an investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/selecta-biosciences-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, ...

  • 2 Biotech Stocks Under $5 With Blockbuster Potential
    TipRanks

    2 Biotech Stocks Under $5 With Blockbuster Potential

    A lot can change after a single trip around the sun. While COVID-19 has had a devastating impact on the economy, CFRA’s chief investment strategist, Sam Stovall, thinks that the market will continue to stage a recovery, with stocks returning to all-time highs in the next year.“In other bear markets going back to 1929, and the average 13-month advance was 50%. We have a very good possibility of retracing our steps and challenging the old high,” Stovall stated. He estimates that the S&P 500 will reach the 3,435 mark in the next twelve months, which from current levels, would reflect a 17% pop as well as surpass the 3,393 high-point hit back on February 19.That’s not to say the reopening of the economy won’t bring about a second wave of COVID-19 infections, but Stovall argues that even if this occurs, the U.S. government’s huge stimulus packages should mitigate the impacts. “We’ve had a lot of people compare it with the crash of ’29, the depression of the 1930s, etc. But back then, you had the government actually tightening their reins, balancing their budget — you did not have a reactive Federal Reserve. Whereas today, you have the exact opposite,” Stovall explained.With this in mind, investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage. Not only do you get more bang for your buck, but also even minor share price appreciation can result in major percentage gains. However, other market watchers believe that these bargain prices are too good to be true, noting there could be a very good reason a particular ticker is trading at such low levels.Taking the risk into consideration, we used TipRanks’ database to pinpoint two penny stocks within the healthcare sector that look especially promising; each boasts a “Strong Buy” consensus rating from the analysts and sky-scraping upside potential.Strongbridge Biopharma (SBBP)With one rare disease asset, Keveyis, already available and a Phase 3 candidate, Recorlev, Strongbridge could potentially transform the treatment paradigm. Bearing this in mind, ahead of the upcoming Recorlev data release in the third quarter of 2020, several members of the Street believe that its $2.86 share price reflects the ideal entry point.In a recent update, management stated that the Phase 3 LOGICS data readout for Recorlev in Cushing's syndrome is right on track, with 41 out of 42 patients having already completed the randomized withdrawal phase. In addition, another patient should be enrolled any day now. According to Oppenheimer’s Hartaj Singh, there is a “clear path to top-line data in 3Q20," noting that the completion of 41 patients suggests that the COVID-19 disruption will have a limited impact on the quality of the data. Singh also thinks that the Recorlev supply should be enough to last throughout the trial. The 5-star analyst added, “Following a positive readout, an NDA submission for Recorlev could be filed within ~six months, after which a standard 10-month review cycle would be expected. We anticipate a launch in late 2021/early 2022.” To this end, the data readout could drive massive upside.Despite the fact that SBBP faces competition, Recorlev's profile is clinically relevant, in Singh’s opinion. “Recorlev's profile could not only convert ketoconazole switches but also the existing branded products. From our physician research, we found the dissatisfaction with pasireotide (Signifor), whose diabetes risk is contraindicated with Cushing's, as an opportunity for disruption. In this vein, we believe the improvements on metabolic and other metrics can be particularly meaningful for Recorlev commercially,” he commented.Singh also points out that Cushing's launch could benefit from the ultra-orphan primary periodic paralysis (PPP) market. “The successful efforts to build strong patient support services and management are likely to translate well into Cushing's, a population which can be challenging to manage due to the complexity of their disease, co-morbidities, and high unmet need,” he noted.As Singh believes SBBP is an “underappreciated name with significant risk/reward potential," he reiterates an Outperform (i.e. Buy) rating, along with a $6 price target, which implies a 104% upside potential from current levels. (To watch Singh’s track record, click here) Turning now to the rest of the Street, other analysts also like what they’re seeing. 3 Buys and no Holds or Sells have been assigned in the last three months, making the consensus rating a Strong Buy. At $12, the average price target puts the upside potential at a whopping 320%. (See Strongbridge stock analysis on TipRanks)Selecta Biosciences (SELB)Our second pick is Selecta Biosciences, which is working on overcoming immunogenicity with its innovative ImmTOR immune tolerance platform. With top-line data from the COMPARE Phase 2 study of its SEL-212 candidate in severe gout expected in Q3 of this year, the analyst community thinks that at $3.24 apiece, now is the time to snap up shares. Weighing in on SELB for Canaccord, five-star analyst John Newman sees the upcoming data readout as a major catalyst for shares. “We expect SEL-212 to show a large and statistically significant improvement for serum uric acid control vs Krystexxa in COMPARE, which should move the stock significantly higher during 3Q20. We believe the study is highly powered to show a statistically significant benefit for SEL-212,” he stated.Newman also argues that the data from patients that didn’t receive all of the infusions should still be factored into the results. Expounding on this, he said, “Also, very importantly, patients who drop out of the study due to a missed infusion should still be included in the study, in our view, meaning study powering should not be affected. This is the same statistical treatment used in the original Phase 3 Krystexxa studies.”Looking more closely at the baseline serum uric acid (SUA) enrollment requirements, they are identical for both the SEL-212 and Krystexxa arms. According to Newman, this means the efficacy difference will be clearly interpretable. It should also be noted that SELB did change the baseline SUA measurement in order to accelerate enrollment, but as both arms were equally impacted, the analyst thinks the alteration is irrelevant.While some investors expressed concern regarding COVID-19's impact on the data readout, half of the patients had already completed the study as of April, and flexibility regarding the location of blood draws and infusion frequency limits the impact as well.To this end, Newman left his Buy rating and $13 price target unchanged. Should this target be met, a twelve-month gain of 301% could be in the cards. (To watch Newman’s track record, click here)What does the rest of the Street think about SELB’s long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings have been received in the last three months, 7 to be exact, so the consensus rating is a Strong Buy. Not to mention the $7.83 average price target implies 139% upside potential. (See Selecta stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Call Transcript
    Motley Fool

    Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Call Transcript

    Joining me today is Carsten Brunn, our President and Chief Executive Officer; and Brad Dahms, our Chief Financial Officer. In addition, Kei Kishimoto, our Chief Scientific Officer, will be available for the Q&A portion of the call.

  • GlobeNewswire

    Selecta Biosciences Reports First Quarter 2020 Financial Results

    - Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 - - Phase 3 clinical program of SEL-212 to commence in 2H.

  • SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Selecta Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
    PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Selecta Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

    Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Selecta Biosciences, Inc. (NASDAQ: SELB).

  • GlobeNewswire

    Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Bank of America Merrill Lynch 2020 Health Care Conference, which is being held virtually, on Tuesday, May 12 at 5:00 p.m. Eastern Time. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform (ImmTOR).

  • GlobeNewswire

    Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Recent Operational Highlights

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that it plans to host a conference call on Thursday, May 07, 2020, at 8:30 a.m. ET to discuss its first quarter financial results and recent operational highlights. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform (ImmTOR). Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity.

  • GlobeNewswire

    Selecta Biosciences Appoints Dr. Goran Ando to its Board of Directors

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Dr. Goran Ando to its Board of Directors, replacing Amir Nashat, effective April 24, 2020. “The addition of Dr. Ando to our Board means that Selecta now has another proven leader with a successful track record in product development and commercialization,” said Carrie S. Cox, Chairman of the Board, Selecta Biosciences.

  • GlobeNewswire

    Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14 at 10:40 a.m. Eastern Time. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform (ImmTOR).

  • Thomson Reuters StreetEvents

    Edited Transcript of SELB earnings conference call or presentation 12-Mar-20 12:30pm GMT

    Q4 2019 Selecta Biosciences Inc Earnings Call

  • GlobeNewswire

    Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial Results

    - Topline results from head-to-head COMPARE trial of SEL-212 in chronic refractory gout expected in Q3 2020 - - Received guidance from the FDA on SEL-212 Phase 3 clinical trial.

  • GlobeNewswire

    Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on Thursday, March 12, 2020, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2019, and recent operational highlights. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity.

  • 7 Cheap Stocks Under $7 With Massive Upside Potential
    Kiplinger

    7 Cheap Stocks Under $7 With Massive Upside Potential

    Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond

  • 3 Monster Growth Stocks Primed for Further Gains
    TipRanks

    3 Monster Growth Stocks Primed for Further Gains

    When it comes down to it, investors are focused on a single factor: a stock’s ability to deliver returns. As Wall Street observers gauge the strength of a particular investment opportunity, often, they will filter out the noise and instead, concentrate their attention on its long-term growth prospects. We are referring to whether or not a name can achieve sustainable growth over the long haul, handsomely rewarding investors in the years to come.So, with this goal in mind, what’s the first step for investors ready to get down to business? It’s narrowing down the multitude of tickers traded in the public market to a select few that represent the pick of the bunch. To make it into this exclusive group, these names should not only have strong long-term growth narratives, but also the analyst community’s support.Setting out on our own search, we used TipRanks’ Stock Screener tool to pinpoint 3 stocks that have earned “Strong Buy” consensus ratings from the analysts and boast substantial upside potential from current levels.Let’s get started.Selecta Biosciences (SELB)Selecta Biosciences believes that its ImmTOR immune tolerance platform can help patients fight rare diseases. Currently, biologic drugs can trigger neutralizing antibodies (NAbs) that work against the therapy, but ImmTOR technology allows for immune tolerance of the therapy. With this biotech already having gained 107% over the last twelve months, investors want to know if there’s more fuel left in the tank.According to Mizuho Securities analyst Difei Yang, the answer is yes. She highlights the COMPARE trial as being the driving force behind her bullish thesis. The Phase 2 clinical trial is evaluating its lead candidate, SEL-212, in patients with chronic refractory gout, specifically looking at its efficacy in resolving symptoms like flares and gouty arthritis. Based on earlier clinical data, a combined therapy of ImmTOR and pegadricase, the current uricase therapy approved by the FDA, was able to reduce the occurrence of gout flares. As a result, the data allowed SEL-212 to proceed to a head-to-head COMPARE trial, the enrollment of which was completed back in December.Yang argues that the “encouraging” interim data increases the therapy’s likelihood of FDA approval. When looking at the big picture, she is optimistic about the platform as it may lead to a re-dosing of gene therapy. Additionally, she points out that the company was able to cut its financing overhang.Given Yang’s high hopes for SELB, it makes sense that she stayed with the bulls. Not only did she maintain a Buy rating, but she also bumped up the price target from $4 to $7. This new target conveys her confidence in the biotech’s ability to climb 66% higher over the next year. (To watch Yang’s track record, click here)What does the rest of the Street have to say? As it turns out, when it comes to SELB, other analysts are also on board. With 5 Buy ratings assigned in the last three months compared to no Holds or Sells, the word on the Street is that the stock is a Strong Buy. Not to mention the $8.67 average price target puts the potential twelve-month gain at 105%. (See Selecta stock analysis on TipRanks) Ocular Therapeutix (OCUL)This biopharma uses a hydrogel platform to develop innovative treatments for various eye diseases. While its DEXTENZA insert has received FDA approval for the treatment of inflammation and pain following ophthalmic surgery, analysts point to its development pipeline as being capable of driving further growth on top of its already posted 57% one-year rise.On February 7, the company released data from the Phase 1 clinical trial for its OTX-TIC candidate at the Glaucoma 360 conference in San Francisco. The trial is studying the long acting travoprost intracameral implant’s ability to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma or ocular hypertension.The data readout was a major positive for the company, as the candidate was not only able to lower IOP levels very fast, but it also sustained these reduced levels for significant periods of time, 18 months in one case. Adding to the good news, OTX-TIC was found to be well tolerated and safe, with no serious adverse events reported. It should also be noted that OCUL has kicked off the third and fourth cohort enrollment for the Phase 1 trial, and it will continue to monitor the first two cohorts long-term.This trial outcome has certainly impressed Wall Street analysts, namely Yi Chen of H.C. Wainwright. Thanks to the positive data announced so far, the five-star analyst argues that the candidate is more likely to receive approval from the FDA, increasing the pobability from 20% to 30%. To this end, Chen boosted the price target by $2 in addition to reiterating his Buy recommendation. At $8, the new target implies that shares could surge 42% over the next year. (To watch Chen’s track record, click here)Like the H.C. Wainwright analyst, Piper Sandler’s Joseph Catanzaro believes that the data was promising enough to warrant a price target increase. Along with his Overweight rating, the four-star analyst lifted the price target from $5.50 to $7. (To watch Catanzaro’s track record, click here)When looking at other analyst activity, it has been relatively quiet as only one other analyst has published a recent review. That being said, the call was also bullish, making the consensus rating a Strong Buy. Given the $7.33 average price target, a 30% twelve-month gain could be in the cards. (See Ocular Therapeutix stock analysis on TipRanks) Lithia Motors (LAD)Switching gears now, we move on to Lithia Motors, one of the largest car retailers in the U.S. While the name has taken some heat recently, several analysts still see more growth in store for the company, which has already posted a 46% twelve-month gain.In 2019, Lithia became the broadest coast-to-coast car retail network after it expanded its reach to include 92% of the U.S. Currently, the company’s physical network is comprised of 189 stores located across the U.S., with 21 brands of vehicles being represented in California alone.That being said, the auto retailer isn’t finished growing just yet. Last week, Lithia announced that it had acquired two Lexus stores in Sacramento and Roseville, California. According to statements from President and CEO Bryan DeBoer, these two locations could see revenue reach $160 million.Craig-Hallum analyst Ryan Sigdahl doesn’t dispute the fact that the temporary pressure on margins caused him to assume a lower premium to comps. He does remind investors, though, that overall, the company’s most recent quarter was solid. During the quarter, Lithia Motors was able to generate “strong” 7% year-over-year same-store sales growth in a slowing SAAR environment as a result of strength in its used vehicle business. Additionally, the analyst argues that the reason its profits took a hit was its integration of recent acquisitions and its efforts to position itself for a “banner year of growth”.In line with his optimistic approach, Sigdahl tells investors that the recent weakness presents an attractive entry-point. Along with his Buy rating, though, the analyst did reduce the price target from $200 to $170. However, the target still leaves room for a possible twelve-month gain of 31%. (To watch Sigdahl’s track record, click here)Looking at the consensus breakdown, it appears that other Wall Street pros are on the same page. As 100% of the analysts that have issued a recent recommendation see the stock as a Buy, the message is clear: LAD is a Strong Buy. On top of this, the $168 average price target suggests 30% upside potential. (See Lithia Motors stock analysis on TipRanks)

  • GlobeNewswire

    Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Tuesday, February 25 at 11:00 a.m. Eastern Time. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.

  • GlobeNewswire

    AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

    Selecta Biosciences, Inc. (SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of the agreement, AskBio has exercised its option to exclusively license rights to develop and commercialize Selecta’s immune tolerance platform, ImmTOR, for use in adeno-associated virus (AAV) gene therapy for the treatment of Pompe disease. When used in combination with AAV gene therapy vectors, Selecta’s ImmTOR has been shown to inhibit the immune response to the vector (Nature Communications, October 2018).

  • GlobeNewswire

    Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the completion of patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial enrolled 150 patients across 49 sites trial and is evaluating the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout. “There is a demonstrated need for a next-generation treatment for chronic refractory gout, and this trial may reveal important clinical insights that could help physicians best treat patients suffering from this painful, debilitating disease,” said Robert T. Keenan, MD, MBA, MPH, board certified rheumatologist at Duke University School of Medicine and Principal Investigator of the COMPARE trial.

  • GlobeNewswire

    Selecta Biosciences Announces $70 Million Private Placement

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it has entered into definitive agreements to sell securities in a private placement with a group of institutional investors and certain members of the Company’s Board of Directors. The lead institutional investors in the private placement were Vivo Capital LLC, Mangrove Partners, EcoR1 Capital LLC, BVF Partners L.P., and Boxer Capital LLC. The transaction is expected to result in gross proceeds to the company of approximately $70 million, before deducting placement agent fees and other offering expenses.

  • Hedge Funds Have Never Been This Bullish On Selecta Biosciences, Inc. (SELB)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Selecta Biosciences, Inc. (SELB)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 752 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • If You Had Bought Selecta Biosciences (NASDAQ:SELB) Stock Three Years Ago, You'd Be Sitting On A 95% Loss, Today
    Simply Wall St.

    If You Had Bought Selecta Biosciences (NASDAQ:SELB) Stock Three Years Ago, You'd Be Sitting On A 95% Loss, Today

    Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in...

  • GlobeNewswire

    Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of Directors

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Carrie S. Cox to the position of Chairman of the Board of Directors, effective immediately.

  • Thomson Reuters StreetEvents

    Edited Transcript of SELB earnings conference call or presentation 8-Nov-19 1:30pm GMT

    Q3 2019 Selecta Biosciences Inc Earnings Call

  • GlobeNewswire

    Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference

    Selecta Biosciences, Inc. (SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19 at 1:50 p.m. Eastern Time. Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.